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ORIGINAL ARTICLE
Serologic Anti-GP2 Antibodies Are Associated with Genetic
Polymorphisms, Fibrostenosis, and Need for Surgical Resection in
Crohn’s Disease
Frauke Degenhardt,* Andrea Dirmeier,† Rocio Lopez, MS,‡ Sylvia Lang,§ Claudia Kunst, PhD,†
Dirk Roggenbuck, MD, PhD,k Dirk Reinhold, MD, PhD,¶ Silke Szymczak, PhD,*,**
Gerhard Rogler, MD, PhD,§,†† Frank Klebl, MD, PhD,† Andre Franke, PhD,* and Florian Rieder, MD†,‡‡
Background: The presentation of Crohn’s disease (CD) is heterogeneous and often leads to serious complications and need for surgery. We tested
serum anti-zymogen granule glycoprotein 2 (GP2) antibodies, including its novel isoform alpha, for association with genetic variants, diagnosis, disease
stratiﬁcation, and prediction of CD courses in a combined cross-sectional and cohort study.
Methods: Serum samples of 303 CD, 108 ulcerative colitis, 72 other inﬂammatory gastrointestinal diseases, and 206 controls without predominant
gastrointestinal diseases controls (HC) were tested for the presence of Anti-GP2 and Anti-Saccharomyces cervisiae (ASCA) by enzyme-linked immu-
nosorbent assay. Genetic analysis was performed using the Illumina Immunochip.
Results: GP2 IgA and IgG had the highest discriminatory capability for CD versus ulcerative colitis and CD versus inﬂammatory gastrointestinal
diseases. We identiﬁed an association of GP2 IgA and IgG each with 5 distinct single-nucleotide polymorphisms. Levels of anti-GP2 IgG were
moderately associated with ileal disease location. Interestingly, both, anti-GP2 IgA and IgG were exclusively associated with the occurrence of stenosis
and need for surgery, independently of disease location, but not with ﬁstulizing CD, early disease onset or disease activity. ASCA IgG and IgA were
qualitatively and quantitatively linked to CD, CD complications, and need for surgery. Increased levels of ASCA IgG and IgA and positivity for ASCA
IgG, but neither levels nor positivity for GP2 IgG or IgA were predictive of the earlier occurrence of complications or surgery.
Conclusions: Anti-GP2 antibodies may aid as a tool for diagnosis and differentiation of CD and could indicate a more complicated CD course.
(Inﬂamm Bowel Dis 2016;22:2648–2657)
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I nﬂammatory bowel disease (IBD) commonly suffers froma delay in time from the ﬁrst occurrence of symptoms to diag-
nosis.1 Once the diagnosis of IBD is made, its subcategorization
into Crohn’s disease (CD) or ulcerative colitis (UC) is critical for
determining the optimal treatment strategy.2,3 Development of
complicated disease behavior, for the purpose of our study
deﬁned as the occurrence of internal ﬁstulae or stenoses, is a fre-
quent event during the disease course and has important clinical
implications.4,5 New tools are necessary at a clinical level to aid in
the diagnosis and differentiation of IBD or to screen for individ-
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uals particularly susceptible to the development of complicated
CD behavior leading to early surgery—making an early or more
aggressive therapeutical intervention possible.
Over the past decade, serological markers for IBD, such as
anti-Saccharomyces cervisiae (ASCA) have been the focus of
extensive investigation, not only for the diagnosis and differenti-
ation of IBD but also for disease stratiﬁcation.6,7 More recently,
additional serum antibodies have been reported in patients with
CD.8–14 Although ASCA is still the serologic markers with the
highest accuracy, the overall limited precision of the existing
markers restricts their use in clinical practice making testing of
novel markers and panels of markers necessary.
Pancreatic autoantibodies (PAB) are known to be associ-
ated with CD, being present in about up to 42% of patients, but
not with UC or healthy controls.15–17 Recently glycoprotein 2
(GP2) has been identiﬁed as the major target antigen of PAB.18
Since then, few studies investigated the value of anti-GP2 anti-
bodies for diagnosis and differential diagnosis of IBD as well as
the link with disease courses.19–26
Despite this information, several items remain unclear: (1)
Information is lacking comparing IBD to non-IBDs of the intestine
and hence allowing the differentiation of a CD-speciﬁc effect from
a nonspeciﬁc inﬂammatory phenotype. (2) Only a single very
recent publication investigated predictive capabilities for compli-
cated CD.21 (3) The published studies use isotype beta of anti-GP2
and no information is available on the novel isotype alpha of anti-
GP2. (4) Essentially, no information is available about a possible
genetic susceptibility to the formation of anti-GP2 antibodies. This
study was designed to ﬁll these knowledge gaps by evaluating the
ability of anti-GP2 IgG and IgA for distinct objectives: diagnosis
and differentiation of CD, including comparison with other inﬂam-
matory gastrointestinal diseases (OGD), association with and pre-
diction of complicated disease behavior, comparison to an available
gold standard and association with genetic variants.
MATERIALS AND METHODS
Patient Population
Serum samples were obtained from 303 patients with CD
seen at the IBD center of the Department of Internal Medicine I,
University Medical Center Regensburg, Regensburg, Germany.
The sera belong to the serum repository of the German
Competence Network IBD. CD was diagnosed based on clinical,
radiographic, endoscopic, and histopathologic criteria according
to the European Crohn’s and Colitis organization clinical consen-
sus guidelines.3 Patient characteristics are shown in Table 1. All
CD inpatients and outpatients seen at our clinic between 2000 and
2006 were asked to participate in the serum repository. Patients
with indeterminate colitis were excluded because of their low
number, which made a meaningful analysis impossible.
The control groups consisted of 386 individuals: 108
patients with UC, 72 patients with OGD, including non-IBD
gastrointestinal inﬂammation such as diverticulitis/-osis,
infectious colitis, pseudomembranous colitis, chemotherapy-
induced colitis, intestinal vasculitis as well as patients with liver
cirrhosis, a disease known to be accompanied by increased
intestinal permeability, and 206 controls (non-IBD/GI) with no
IBD, no gastrointestinal disorder (e.g., hypertension or diabetes
mellitus only), or no apparent disease. The patients with liver
cirrhosis were included as serologic antibodies associated with
CD were found to be elevated in this patient population.27,28 The
diagnosis of UC was based on clinical, radiographic, endoscopic,
and histopathologic criteria as summarized in the European
Crohn’s and Colitis organization clinical consensus guidelines.2
We additionally performed a cohort study among adult
patients with CD. Only patients without any complications, deﬁned
as ﬁstula or stenoses, and no CD-related surgery before or within
20 days of sample procurement (totally naive population [n ¼ 70];
see Table 1, Supplemental Digital Content 1, http://links.lww.com/
IBD/B353) were included. Patients were excluded if the time from
serum procurement to event was #20 days or if they had a pure
inﬂammatory disease course with a follow-up of less than 3 years.
This patient cohort represents a subgroup of the above reported
cross-sectional study. Follow-up for a particular patient was termi-
nated at the time of the last available patient encounter.
Clinical data including age at and time of diagnosis, body
mass index, gender, date of sample procurement, date, type and
frequency of complications and surgery, disease location, disease
status, and medications were obtained or updated, respectively, for
each time point of sample procurement separately by the treating
physician of the IBD unit. Once collected, data were transferred and
stored in a securely coded pseudonymized database for analysis.
Disease activity was determined as a yes/no by the treating
physician respecting all criteria included in the CDAI. A Crohn’s
disease activity index (CDAI) cutoff of 150 was used. Before ﬁn-
ishing data collection, all patient charts and the database were
reviewed and updated for the data points mentioned above.
Phenotypical Characteristics of Patients
with IBD
Patients with CD were assigned a behavioral phenotype
according to the Montreal Classiﬁcation.29 For the purpose of this
study, complicated disease behavior in patients with CD was
deﬁned as the occurrence of ﬁstula or stenoses before or during
follow-up. For the classiﬁcation of internal penetrating versus
stricturing disease, either cross-sectional imaging was required
or the diagnosis was made post surgical resection through histo-
pathology. Furthermore, we examined the need for CD-related
surgery during the follow-up period. Patients undergoing CD-
associated abdominal surgery were separated from CD-related
perianal surgery, such as perianal abscess drainage or perianal
ﬁstula treatment. Early disease onset was deﬁned according to
the Montreal classiﬁcation as disease onset ,40 years of age.
Serological Analysis
After the blood draw, serum was separated by centrifuga-
tion and kept frozen at2808C until use. Anti-GP2 IgG and IgA as
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well as ASCA IgG and IgA were measured in the serum samples
by enzyme-linked immunosorbent assay in a blinded fashion
without the knowledge of the patients’ diagnosis or other clinical
information and following the manufacturers’ conditions (GA
Generic Assays, Dahlewitz, Berlin, Germany) as reported previ-
ously.30 The optical density obtained is directly proportional to
the amount of antibody. Results were expressed as arbitrary units,
provided by the manufacturer of the enzyme-linked immunosor-
bent assay kits, which is a value relative to a standard serum pool
derived from patients with well-characterized disease found to
react to the above-mentioned antigens.
Two different isoforms of GP2 are synthesized in the
pancreas, a larger isoform (termed alpha) and a shorter isoform
(termed beta).31 GP2 IgA and IgG assays are based on recombi-
nant human GP2 isoforms alpha and beta expressed in Spodoptera
frugiperda 9 cells as solid-phase antigen.30 The anti-GP2 IgA and
IgG enzyme-linked immunosorbent assays displayed an interas-
say variability of 5.0% each for a serum of 26.9 and 18.5 U/mL,
TABLE 1. Patient Characteristics
Factor CD (N ¼ 303) UC (N ¼ 108) OGD (N ¼ 72) Non-IBD/GI (N ¼ 206) P
Female,a n (%) 160 (52.8) 43 (39.8)b 26 (36.1)b 120 (58.8)c,d ,0.001e
Age at sample procurement,a mean 6 SD 36.1 6 12.5b,c,d 40.2 6 12.8b,d,f 60.3 6 13.8 b,c,f 45.9 6 15.4 c,d,f ,0.001g
Body mass index,a mean 6 SD 23.6 6 5.4b,d 24.8 6 5.1 26.8 6 5.7f 26.4 6 6.6f ,0.001g
Age at diagnosis,a mean 6 SD 28.5 6 12.3c 32.9 6 13.1f — — 0.002g
Disease duration,a median (Q1, Q3), mo 68.7 (15.7, 138.0) 60.8 (22.9, 148.1) — — 0.84h
Location (nonexclusive)
Upper GI tract,a n (%) 31 (10.4) — — —
Jejunum, prox. ileum,a n (%) 35 (11.7) — — —
Ileocecal,a n (%) 93 (30.7) — — —
Colon (w/o cecum),a n (%) 43 (14.2) — — —
Ileum and colon,a n (%) 166 (55.0) — — —
Rectum,a n (%) 96 (31.8) — — —
Any ileum involvement,a n (%) 259 (85.5) — — —
Montreal classiﬁcation,a n (%)
B1 69 (22.8) — — —
B1p 21 (6.9) — — —
B2 86 (28.4) — — —
B2p 18 (5.9) — — —
B3 76 (25.1) — — —
B3p 33 (10.9) — — —
Medications at sample procurementa
Inﬂiximab 1 (0.33) — — —
Steroids 150 (49.7) — — —
Immunosuppressant 176 (58.3) — — —
Medications during follow-upa
Inﬂiximab 6 (2.0) — — —
Steroids 172 (57.0) — — —
Immunosuppressant 201 (66.6) — — —
Surgery,a n (%) 219 (72.3) — — —
A signiﬁcance level of 0.008 was used for pairwise ad hoc comparisons. Signiﬁcant values are depicted in bold and italic.
aData not available for all subjects. Missing values: female ¼ 2, age at sample procurement ¼ 2, body mass index ¼ 19, upper GI-tract ¼ 4, jejunum, prox. ileum ¼ 4, ileocecal ¼ 4,
ileum and colon ¼ 1, rectum ¼ 1, ileum involvement ¼ 1, medications ¼ 1.
bSigniﬁcantly different from non-IBD/GI.
cSigniﬁcantly different from UC.
dSigniﬁcantly different from OGD.
eP-values ¼ Pearson’s chi-square test.
fSigniﬁcantly different from CD.
gP-values ¼ analysis of variance.
hP-values ¼ Kruskal–Wallis test.
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respectively.32 The functional assay sensitivity representing the
lowest antibody concentration with a coefﬁcient of variation of
smaller than 20% was determined at 2.4 and 1.8 U/mL for anti-
GP2 IgG and anti-GP2 IgA, respectively.33 For ASCA IgG and
IgA, the interassay coefﬁcient of variation was 5.9% for a sample
containing 72 U/mL and 1.8% for a sample containing 81 U/mL
of ASCA IgA and ASCA IgG, respectively. Antinuclear antibody,
anti-PR2 antibody, and anti-myeloperoxidase antibody were mea-
sured in all serum samples following the manufacturers’ instruc-
tions (GA Generic Assays).
Accuracy Analysis and Cutoff Values
For the purpose of our study, we evaluated the antibody
markers for distinct clinical objectives: presence in CD, diagnosis
of CD, and differentiation between CD and UC, OGD and non-
IBD/GI, quantitative and qualitative association or prediction of
the serum antibodies with disease phenotypes, namely the
occurrence of complications, IBD-related surgery, early disease
onset and disease location, and association of anti-GP2 level with
genetic variants. Receiver operating characteristics (ROC) curves
were calculated by plotting sensitivity versus (1-speciﬁcity) for
each individual marker. Based on the ROC curves, cutoff values
were determined for each clinical scenario, optimizing speciﬁcity.
Genotyping and Quality Control
Genotyping and quality control can be found in supple-
mental methods (see Fig. 2, Supplemental Digital Content 2,
http://links.lww.com/IBD/B354).
Statistical Analysis
Data are presented as mean 6 SD, median (25th, 75th per-
centiles), or n (%). Univariate analysis was performed to assess
differences between the disease groups. Analysis of variance or
the nonparametric Kruskal–Wallis tests were used for continuous
or ordinal variables, and Pearson’s chi-square tests were used for
categorical factors. In addition, ROC curves were constructed and
the areas under the curves (AUCs) with their corresponding 95%
conﬁdence intervals (CIs) were estimated. Using the cutoff values
for each marker as suggested by the ROC curves, antibody posi-
tivity was determined for each subject. Sensitivity, speciﬁcity, and
positive and negative predictive values were estimated to assess the
validity of each marker in diagnosing CD. We assessed a possible
association of anti-GP2 and anti-ASCA serum levels with available
variables. We tested for association with body mass index (catego-
rized in,25 and$25) and gender using an unpaired 2-sided t test,
assuming equal variance and with age (categorized into the inter-
vals 0–20, 21–40, 41–60, and above 60) using analysis of variance
and R version 3.0.2 (R Institute for Statistical Computing, Vienna,
Austria). A time-to-event analysis was performed to assess whether
antibodies are associated with occurrence of ﬁrst complication and/
or surgery. Time of follow-up was deﬁned as months between the
time of antibody levels determination and the occurrence of ﬁrst
event or last record of patient history if no events were observed.
Kaplan–Meier plots were constructed and log-rank tests were used
to assess differences in event-free rates between groups. In addition,
univariable and multivariable Cox proportional hazard models were
constructed, and the hazard ratios (HRs) and 95% CIs for each
marker were estimated. For other analyses, SAS version 9.2 (The
SAS Institute, Cary, NC) and R version 3.0.1 were used. For all
statistical tests, a P-value of ,0.05 was considered statistically
signiﬁcant.
Analysis Genome-Wide Association Study
Genome-wide association (GWA) study can be found in
supplemental methods Fig. 2, Supplemental Digital Content 2,
http://links.lww.com/IBD/B354.
Ethical Considerations
Signed informed consent was obtained from all partici-
pants. The study was approved by the ethics committee of the
University of Regensburg.
RESULTS
Clinical Phenotypes of the Population
A total of 689 unrelated participants were eligible for
analysis (Table 1). The largest differences between the cohorts
were found for age at sample procurement. Two hundred thirteen
patients with CD had a complication, deﬁned as ﬁstula or stric-
ture, before or at the time of sample procurement. After a median
follow-up, after sample procurement of 59.8 months, the total
number of patients with CD who experienced a disease compli-
cation increased to 230. Ninety-one of the patients with compli-
cated disease behavior had both, ﬁstulae and stenoses. Two
hundred nineteen patients with CD already had IBD-related sur-
gery at the time of sample procurement. Eleven additional patients
with CD had surgery during follow-up.
Presence of Anti-GP2 Antibodies in CD and
Use for Diagnosis and Differentiation
Levels of anti-GP2 isoform beta antibodies were signiﬁcantly
higher in CD than in all control groups (Table 2; P, 0.001). Since
the cutoff values and discriminatory capability of the novel anti-
GP2 antibodies have not been uniformly standardized in patients
with CD, we initially tested the immune responses of each individ-
ual marker for 4 different settings: Differentiation of CD versus
non-CD, CD versus UC, CD versus OGD, and CD versus non-
IBD/GI. For this purpose, ROC curves were generated for each
individual marker (Fig. 1). GP2 IgA and GP2 IgG isoform beta
were the markers with the highest discriminatory accuracy with
AUC values between 0.67 and 0.8 (see Table 2, Supplemental
Digital Content 3, http://links.lww.com/IBD/B355). Based on the
ROC curves, optimal cutoff values were determined. The propor-
tion of the positive markers in the different cohorts is shown in
Table 2. 25.4% and 19.8% of the participants were positive for anti-
GP2 IgA or IgG isoform beta, respectively, which was higher than
all other control groups. Based on the cutoff values, we tested the
validity of each single marker for the conditions CD versus all other
Inﬂamm Bowel Dis  Volume 22, Number 11, November 2016 GP2 and CD
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groups, CD versus UC, CD versus OGD, and CD versus non-IBD/
GI (see Table 3, Supplemental Digital Content 4, http://links.lww.
com/IBD/B356). Anti-GP2 isotype 4 had a high speciﬁcity and
positive predictive value and low sensitivity and negative predictive
value for all tested conditions.
As a control, we evaluated the so far most accurate marker
associated with CD ASCA IgG and IgA in our cohort. Although
both ASCA antibody levels were higher in CD than in UC and
non-IBD/GI, the frequency was only different compared with the
UC subjects. Anti-GP2 isotype 4 antibodies had a higher AUC
and speciﬁcity for all tested conditions. Next, we assessed
a possible overlap of ASCA and anti-GP2 isotype 4 in our
patients with CD. The Venn diagram can be seen online in Fig. 1,
Supplemental Digital Content 5, http://links.lww.com/IBD/B357,
showing positivity of these markers in distinct patient populations
as well as an overlap between anti-GP IgG and IgA as well as
anti-GP2 and ASCA. We also separated the OGD group into
subjects with liver cirrhosis and those without for analysis of
marker expression. This information can be found in Table 4,
Supplemental Digital Content 6, http://links.lww.com/IBD/B358.
Antibody Response and Association with
Disease Phenotypes
The response of each individual marker was tested
separately for association with complicated disease behavior,
need for surgery, ileal disease location, clinically active disease
and CRP values. Since this area is less explored, we additionally
evaluated the novel isoform alpha of anti-GP2 in this setting. A
Venn diagram depicting overlap for positivity of anti-GP2 can be
found in Fig. 2, Supplemental Digital Content 7, http://links.lww.
com/IBD/B359. The univariate analysis for association with dis-
ease phenotypes can be found in Table 5, Supplemental Digital
Content 8, http://links.lww.com/IBD/B360.
In multivariate analyses, taking into account early disease
onset and ileal involvement as potential confounder, we found an
association of anti-GP2 IgG isoform alpha and beta levels with
ﬁbrostenosis and anti-GP2 IgG isoform alpha with need for
surgery (Table 3). Positivity for GP2 IgG and IgA isoform alpha
was linked to a higher risk for complications, ﬁbrostenosis, and
need for surgical intervention but not ﬁstulizing disease. Positivity
for GP2 IgG isoform beta was associated with higher risk for
complications, ﬁstulae, stenoses, and surgery, whereas GP2 IgA
isoform beta was linked to higher risk for ﬁstulae and surgery.
Next, we evaluated the discriminatory ability of anti-GP2 anti-
bodies for disease phenotypes. GP2 IgG and A Isoforms alpha
and beta had an AUC of 0.6 to 0.645 for its association with
ﬁbrostenosis and surgery. The discriminatory capability was not
different from ASCA IgG. The addition of ASCA IgG to GP2 IgG
or IgA of either isoform did not increase its discriminatory abil-
ities (data not shown).
TABLE 2. Marker Distribution
Factor CD (N ¼ 303) UC (N ¼ 108) OGD (N ¼ 72) Non-IBD/GI (N ¼ 206) P
Marker distribution
GP2 IgA isoform beta 5.6 (2.1–15.6)a,b,c 1.2 (1.00–2.2)d 1.8 (1.00–2.9)d 1.5 (1.00–2.6)d ,0.001e
GP2 IgG isoform beta 6.6 (4.1–12.8)a,b,c 3.5 (2.2–7.4)d 3.5 (2.2–6.7)d 4.2 (2.9–7.1)d ,0.001e
ASCA IgA 10.9 (2.9–51.2) 15.8 (11.7–20.0) 17.8 (14.0–32.9) 17.4 (11.0–27.2) 0.013e
ASCA IgG 17.7 (5.2–52.9)a,c 6.4 (4.1–12.6)d 11.4 (4.8–19.2) 7.9 (3.5–15.1)d ,0.001e
Marker positivity
GP2 IgA isoform beta .15 77 (25.4)a,b,c 0 (0.0)d 0 (0.0)d 3 (1.5)d ,0.001f
GP2 IgG isoform beta .15 60 (19.8)a,c 6 (5.6)d 6 (8.3) 11 (5.3)d ,0.001f
ASCA IgA .20 132 (43.6)a 27 (25.0)b,d 32 (44.4)a 73 (35.4) 0.004f
ASCA IgG .20 132 (43.6)a 27 (25.0)b,d 32 (44.4)a 73 (35.4) 0.004f
No. positive markers ,0.001e
0 133 (43.9)a,c 77 (71.3)d 40 (55.6) 129 (62.6)d
1 33 (10.9) 4 (3.7) 0 (0.0) 4 (1.9)
2 66 (21.8) 25 (23.1) 26 (36.1) 64 (31.1)
3 48 (15.8) 2 (1.9) 6 (8.3) 8 (3.9)
4 23 (7.6) 0 (0.0) 0 (0.0) 1 (0.49)
Values presented as Median (P25, P75) or n (%). A signiﬁcance level of 0.008 was used for pairwise ad hoc comparisons. Signiﬁcant values are depicted in bold and italic.
aSigniﬁcantly different from UC.
bSigniﬁcantly different from OGD.
cSigniﬁcantly different from non-IBD/GI.
dSigniﬁcantly different from CD.
eP-values ¼ Kruskal–Wallis test.
fP-values ¼ Pearson’s chi-square test.
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As previously described,34 ASCA IgG and ASCA IgA were
associated with the occurrence of any complication, ﬁstulae, stric-
tures, need for surgery, ileal involvement, and early disease onset.
After correction for ileal disease, location and early disease onset
ASCA IgG and IgA remained associated with any complication,
ﬁstula, stricture, and need for surgery (Table 3).
Antibody Response and Prediction of
Disease Progression
Predictive information for anti-GP2 antibodies is still
limited.21 To obtain prospective information, we performed
a cohort study using a subgroup of 70 patients with a purely
inﬂammatory phenotype at time of sample procurement (see
Table 1, Supplemental Digital Content 1, http://links.lww.com/
IBD/B353). Sera were taken close to diagnosis (median 11.1
months, P25 1.8; P75 50.4) and both isoforms of anti-GP2 were
determined. The median follow-up in the complication and
surgery-naive group was 59.8 months. Among the naive patients
studied, 24.3% experienced any complication during follow-up
(11.4% ﬁstulae, 17.1% stenoses). 15.7% had to undergo CD-
related surgery during the observation period. The predictive sub-
group was compared to the remainder of the included CD subjects
(complication at or before sample procurement). There was no
difference in demographics, disease characteristics, medication
intake, or antibody levels or positivity, with the exception of
GP2 isoform 4 IgA with a slightly higher level and frequency
in the complication at or before sample procurement group
(52.6% positive versus 35.7% positive, P ¼ 0.013, data not
shown).
In the naive patients progressing to a ﬁrst event, deﬁned as
ﬁstula, stenosis, or IBD-related surgery (composite endpoint), the
frequency of antibody positivity or antibody levels of anti-GP2
IgG or IgA isoforms alpha and beta were no different from the
naive patients not progressing to a more complicated disease
course (see Table 6, Supplemental Digital Content 9, http://links.
lww.com/IBD/B361). The same was true for looking at progres-
sion to stricture and/or ﬁstulizing disease or strictures or ﬁstulas or
need for surgery separately (data not shown).
As a positive control, we used ASCA IgG and IgA. The
frequency of antibody positivity or antibody levels for both were
higher in the patients showing a faster progression to ﬁstula,
stenosis, or IBD-related surgery (composite endpoint; see Table 6,
Supplemental Digital Content 9, http://links.lww.com/IBD/B361)
as previously reported using a different ASCA assay.35 Levels
FIGURE 1. ROC for diagnosis and differentiation of CD. A, CS versus non-CD; (B) CD versus UC; (C) CD versus OGD; (D) CD versus non-IBD/GI
controls. The plots for anti-GP2 refer to isoform beta.
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and frequency for ASCA IgG were higher in patients with a faster
progression to ﬁstula and/or stenosis. Levels of ASCA IgA were
elevated in patients with a faster progression to surgery (HR 1.08
[1.02, 1.1]) and positivity for ASCA IgG was higher in patients
with faster progression to surgical intervention (HR 3.7 [1.1,
12.6]). Examples for survival curves for anti-GP2 isoform beta
and ASCA can be found in Fig. 3, Supplemental Digital Content
10, http://links.lww.com/IBD/B362.
We tested whether the use of steroids or immunosuppres-
sants at the time of sample procurement could inﬂuence the marker
levels or positivity. At large, there was no association of medication
intake and serologic marker expression with the exception of
a slightly lower frequency (but not level) of GP2 isoform 1 IgA in
patients taking corticosteroids (66.7% versus 41%, P ¼ 0.035, data
not shown). Since the formation of anti-GP2 antibodies could
indicate an autoimmune phenomenon, we measured all serum sam-
ples for antinuclear antibody, anti-PR2 antibody, and anti-
myeloperoxidase antibody and assessed their ability for diagnosis,
discrimination, and association or prediction of disease phenotypes,
but none of those markers revealed any link (data not shown).
Genotype–Serotype Association
Serologic antibodies linked to CD have been shown to be
familial traits,36 indicating that genetic variants could have an inﬂu-
ence on the expression of serologic markers. To investigate possible
genetic variants linked to the levels of anti-GP2 antibodies, we
performed a GWA analysis on genotypes using the Illumina Im-
munochip genotyping array. For the analysis of anti-GP2 IgA and
anti-GP2 IgG, a total of 519 samples were available. Since isotype
alpha was only available for the CD cohort, we used isotype beta
for the genetic analysis. The analysis had an inﬂation factor of 1.00
(GP2 IgA) and 1.02 (GP2 IgG). The Manhattan quantile–quantile
of all analyses can be found in Figs. 4–6, Supplemental Digital
Content 11, http://links.lww.com/IBD/B363. Owning to the limited
sample size, we lowered the P-value threshold to a level of 1024. In
total, 7 variants were selected for GP2 IgA and 5 for GP2 IgG. No
variants overlap. The variant with the lowest P-value across all
chromosomes is located on chromosome 11 at position 76334404
with a nominally signiﬁcant P-value of 2.59 · 1026 (beta ¼ 0.194,
95% CI [0.114, 0.274]). This variant is located approximately
34 kB downstream of LRCCR32 with has been described, among
others, in the context of CD and UC. In addition, we performed an
LD-based clumping to identify “local best single-nucleotide poly-
morphisms (SNPs)” as described in the Materials and Methods
section. The local best SNPs were paired with imputed markers that
had a lower association P-value within the same region. These
variants, as well as the local effect of these variants and regional
plots, are shown in Table 4, Tables 7 and 8, Supplemental Digital
Content 12, http://links.lww.com/IBD/B364 and Figs 4–6, Sup-
plemental Digital Content 11, http://links.lww.com/IBD/B363. All
markers are preselected based on the regional plots. The majority of
selected variants are intergenic, intronic, or downstream and
upstream variants of their respective genes with unknown func-
tions. Genes selected with the regional plot are shown in brackets.
These can mainly be linked to IBD-related diseases (CD and UC)
and neurological diseases like Alzheimer’s, autism and narcolepsy.
TABLE 3. Odds Ratios for the Association of Markers with Disease Phenotypes Adjusted for Early Disease Onset
and Ileum Involvement
Factor
Any Complication Fistula Stenosis Surgery
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Levels
GP2 IgA iso alpha 1.03 (0.96–1.1) 0.39 1.04 (0.98–1.09) 0.2 1.09 (1.00–1.2) 0.057 1.1 (0.97–1.2) 0.13
GP2 IgG iso alpha 1.07 (0.99–1.2) 0.079 1.01 (0.97–1.04) 0.66 1.07 (1.01–1.1) 0.016 1.1 (1.01–1.2) 0.035
GP2 IgA iso betaa 3.5 (0.75–16.6) 0.11 1.3 (0.92–1.9) 0.12 1.8 (0.95–3.6) 0.071 2.4 (0.85–7.0) 0.098
GP2 IgG iso betaa 1.1 (0.99–1.3) 0.065 1.02 (0.98–1.06) 0.31 1.08 (1.02–1.2) 0.014 1.08 (1.00–1.2) 0.054
ASCA IgA 1.06 (1.01–1.1) 0.017 1.03 (1.01–1.06) 0.021 1.04 (1.01–1.08) 0.008 1.1 (1.05–1.2) ,0.001
ASCA IgG 1.2 (1.08–1.3) ,0.001 1.06 (0.99–1.1) 0.083 1.1 (1.05–1.2) 0.001 1.2 (1.08–1.3) ,0.001
Positvity
GP2 IgA iso alpha $2.6 2.0 (1.1–3.5) 0.018 1.6 (0.98–2.7) 0.058 2.1 (1.2–3.4) 0.005 3.0 (1.8–5.2) ,0.001
GP2 IgG iso alpha $7.3 2.2 (1.2–3.9) 0.008 1.4 (0.88–2.2) 0.15 2.0 (1.2–3.2) 0.006 2.8 (1.6–4.8) ,0.001
GP2 IgA iso beta $1.3a 1.6 (0.90–2.7) 0.12 1.9 (1.2–3.1) 0.006 1.5 (0.96–2.5) 0.071 2.5 (1.5–4.3) ,0.001
GP2 IgG iso beta $1.7a 2.5 (1.4–4.4) 0.002 2.0 (1.2–3.4) 0.009 1.7 (1.02–2.9) 0.042 2.8 (1.6–4.8) ,0.001
ASCA IgA $5.5 5.3 (2.9–9.8) ,0.001 2.3 (1.4–3.9) 0.001 3.5 (2.1–5.8) ,0.001 5.7 (3.2–10.2) ,0.001
ASCA IgG $25.2 4.0 (2.1–7.7) ,0.001 1.8 (1.1–3.0) 0.014 2.7 (1.6–4.5) ,0.001 4.5 (2.4–8.4) ,0.001
ORs for marker levels correspond to a 10-unit increase in the markers. Signiﬁcant values are depicted in bold and italic.
aData not available for all subjects. Missing values: GP2 isoform beta IgA ¼ 1, GP2 isoform beta IgG ¼ 1.
CI, conﬁdence interval; iso, isoform; OR, odds ratio.
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DISCUSSION
We tested 2 isoforms of 2 novel serum antibodies anti-GP2
IgA and IgG for diagnosis and differentiation of IBD as well as
stratiﬁcation and prediction of CD courses in a large, well-
deﬁned, and well-controlled German cohort. The tested serum
markers were associated with CD and had a high discriminatory
capability for CD versus UC. The immune response directed
against GP2 isoform alpha was associated exclusively with
stricturing disease behavior and need for IBD-related surgery.
Anti-GP2 IgG was associated with ileal disease location. Inter-
estingly, none of the antibodies was predictive of disease
phenotypes. A GWA study of antibody expression in our cohort
identiﬁed distinct loci associated with levels of anti-GP2 isoform
beta IgG and IgA, many of which are known susceptibility loci for
IBD.
PAB are known to be associated with CD.15,17 Recently,
glycoprotein 2 has been identiﬁed as the major target antigen of
PAB.18 It is not only present in pancreatic acinar cells but also in
M cells of intestinal Peyer’s patches. M cells are crucial in pre-
senting luminal components to the underlying mucosa-associated
immune system. Although direct proof is missing, this possibly
explains its auto-antigenicity in patients with CD.37 Mucosal GP2
mRNA is increased in antibody-positive patients with CD,18 and
release of GP2 secondary to intestinal damage could induce an
antigenic response. M cells are abundant in the small intestine, in
particular the ileum, and they are essentially absent in the large
intestine.38
This could also explain the higher levels in CD subjects, in
which 25% to 30% are positive for anti-GP2 IgG and/or IgA
antibodies, whereas the frequency is lower in UC (9%–12%) or
controls (0%–8%).33,39 The link to disease location was conﬁrmed
in previous studies showing an association of anti-GP2 with ileal
but not colonic CD.19,20,32 Interestingly, anti-GP2 can also be
detected in higher levels in the serum and feces of patients with
ileal pouch–anal anastomosis with pouchitis than in normal pouch
patients.40 It, however, remains unclear why only a fraction of
patients with CD loose tolerance and develop anti-GP2 antibodies
and if these markers are an epiphenomenon of intestinal damage
or a pathogenetic factor. GP2 recognizes FimH, expressed on the
outer membrane of some enterobacilli, such as Escherichia coli
and Salmonella enterica,37 and facilitates phagocytosis. The
presence of the respective FimH-positive strains in some but not
other CD patients’ microﬂora might provide a potential explana-
tion for the subgroup of GP2-positive CD subjects. The fact that
even anti-GP2-negative patients develop disease makes a direct
pathogenetic relevance less likely. The accuracy of anti-GP2 for
the discrimination of CD from all other groups was higher than
ASCA. Although the low sensitivity of anti-GP2 indicates a lim-
ited clinical value for the primary diagnostic workup of CD, it
could be useful after a thorough clinical workup in cases of
indeterminate differentiation of CD versus UC.
Fibrostenosing complications in CD have been associated
with a higher frequency of anti-GP2 isotype beta IgG in
a Hungarian cohort,26,32 and penetrating complications seem to
have lower prevalence of anti-GP2 IgG. This speciﬁc association
was conﬁrmed by us but was not found by others.21 We addition-
ally tested the novel isoform alpha of anti-GP2 that had compa-
rable accuracy in disease stratiﬁcation. The ability to differentiate
ﬁbrostenosis from ﬁstulizing disease is unique and has not been
reported for ASCA that is elevated in both. There is agreement
TABLE 4. Post Imputation Association Statistics of Markers with Genotypes; SNP with the Lowest P-value
in 6400 kb Region
CHR ID POS REF ALT MA MAF R2 Beta (95% CI) P
GP2 IgA (log10) 2 chr2:38392952 38392952 T C A 0.359 0.607 20.114 (20.169 to 20.060) 4.90 · 1025
2 chr2:184086397 184086397 C T C 0.242 0.473 20.155 (20.233 to 20.077) 1.14 · 1024
2 chr2:205829991 205829991 C T C 0.441 0.998 20.110 (20.165 to 20.054) 1.32 · 1024
11 chr11:76334404 76334404 A G G 0.126 0.999 0.194 (0.114 to 0.274) 2.59 · 1026
GP2 IgG (log10) 2 chr2:103115860 103115860 C G A 0.059 1.001 20.219 (20.327 to 20.111) 7.81 · 1025
3 chr3:33065715 33065715 C G G 0.019 0.732 0.435 (0.248 to 0.623) 6.59 · 1026
12 chr12:78377963 78377963 T C A 0.081 0.238 0.284 (0.147 to 0.421) 5.55 · 1025
13 chr13:44901189 44901189 G A A 0.073 0.997 0.232 (0.129 to 0.336) 1.33 · 1025
19 chr19:51719479 51719479 A T C 0.426 0.577 20.106 (20.158 to 20.054) 6.70 · 1025
GP2 IgA (residuals) 2 chr2:38402571 38402571 T A A 0.367 0.738 20.088 (20.129 to 20.046) 4.85 · 1025
2 chr2:184140295 184140295 C T C 0.297 0.285 0.103 (0.044 to 0.161) 5.83 · 1024
2 chr2:205829991 205829991 C T C 0.441 0.998 20.089 (20.132 to 20.047) 4.63 · 1025
11 chr11:76029879 76s879 T C G 0.488 0.673 20.063 (20.104 to 20.022) 3.05 · 1023
Positions are given in hg19; all calculations were performed on the ALT alleles.
ALT, alternative allele (according to imputation reference); CHR, chromosome; ID, sample identity number; MA, minor allele; MAF, minor allele frequency; POS, position; R2,
imputation accuracy according to Michigan Imputation Server; REF, reference allele (according to imputation reference).
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between studies about a link of GP2 with need for surgical inter-
vention.19,21 This indicates that anti-GP2 could aid in the stratiﬁ-
cation of patients with IBD. It has to be mentioned that all but one
study21 are cross-sectional in design. GP2 IgA predicted a faster
progression to ﬁrst surgical resection in a univariate analysis, but
this predictive capability got lost after correction for gender and
clinical variables,21 a ﬁnding that is comparable to our investiga-
tion in which none of the anti-GP2 antibodies, including its new
isoform, are predictive of the later occurrence of complications.
Only one investigation to date assessed a possible link
between a single gene and anti-GP2 expression in CD.21 There
was no association between anti-GP2 and NOD2/CARD15 var-
iants. In our GWA analysis, several candidates for an association
of SNPs with anti-GP expression were identiﬁed. The majority of
selected variants are intergenic, intronic, or downstream and
upstream variants of their respective genes with unknown func-
tions. The majority of the genes selected with the regional plots
can be linked to IBD and neurological diseases. The variant with
the strongest association is located approximately 34 kB down-
stream of LRCCR32 with has been described, among others, in the
context of IBD. This suggests that susceptibility loci for IBD lead
to a stronger immune response towards GP2.
Antibody stability would be an important feature of
a serologic marker. Pavlidis et al19 reported that 3 of 8 seropos-
itive patients with CD became negative over time, whereas 2 of 12
negative patients with CD turned positive during a median follow-
up of 3 years. Papp et al21 reported stability in antibody status in
.95% of cases, and stability was not affected by the development
of disease complications or the occurrence of surgery. GP2 is not
the only identiﬁed antigen for the previously described anti-
pancreas antibodies. The CUB and zona pellucida-like domains
1 (CUZD1) protein could be an alternate target. In an elegant
study, Papp et al21 showed that anti-CUZD1 is linked to CD
and earlier development of perianal disease.
This study has several limitations: Our hospital is a regional
referral center for severe CD cases introducing a selection bias. It
would be desirable to test this antibody panel in a population-
based cohort. This is reﬂected by the high frequency of patients
with CD with complicated disease behavior and CD-related
surgery. Not all patients who were assigned a behavioral disease
phenotype according to the Montreal classiﬁcation have the
desired follow-up time of 5 years as suggested by Silverberg
et al.41 The sample size is robust but could be considered limited
for the performance of a GWA study, and these results should be
conﬁrmed in independent studies.
CONCLUSIONS
The authors of this article believe that currently no
serologic marker alone is accurate enough for the herein tested
phenotypes, and a combination of markers and modalities shall be
used for disease stratiﬁcation and prediction. Anti-GP2 anti-
bodies, including its isoform alpha, while carrying a high
speciﬁcity, exhibit a rather low sensitivity for the diagnosis of
CD. Anti-GP2 may be helpful in conjunction with other markers
for disease stratiﬁcation given the exclusive link with (but not
prediction of) ﬁbrostenotic disease phenotypes. A genetic associ-
ation of IBD susceptibility SNPs with expression levels of anti-
GP2 antibodies links disease pathogenesis with the formation of
anti-pancreas antibodies.
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